DRNIX Fees and Costs — BNY Mellon Alternative Diversifier Strategies Fund, Class I
Data updated: 2023-06-28
The net expense ratio is 1.74%. There are no sales loads or redemption fees. Portfolio turnover was 14%.
DRNIX Fees and Expenses
Annual operating expenses and sales charges of DRNIX. Prospectus, as of October 31, 2022.
| Annual operating expenses | |
|---|---|
| Management fee | 0.25% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.23% |
| Gross expense ratio | 1.74% |
| Fee waiver | — |
| Net expense ratio | 1.74% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 0.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
DRNIX Costs Over Time
On $10,000 invested in DRNIX, assuming 5% a year before costs, total costs come to $1,072 over 5 years, cutting the return by 1.83% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 1.74%) | $183 | $566 | $973 |
| Lost growth on money paid in costs | $0 | $28 | $99 |
| Total costs | $183 | $594 | $1,072 |
| Value after costs | $10,317 | $10,982 | $11,690 |
| Impact on return, per year | 1.83% | 1.83% | 1.83% |
DRNIX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending October 31, 2022.
- Explicit cost rate (commissions ÷ average net assets): —
- Total broker commissions: —
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 14%
- Securities lending: none during the year
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.